참고문헌
- Burris HA III, Moore MJ, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patient with advanced pancreas cancer: a randomised trial. J Clin Oncol, 15, 2403-13. https://doi.org/10.1200/JCO.1997.15.6.2403
- Colucci G, Giuliani F, Gebbia V, et al (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the gruppo oncologico dell'Italia Meridionale. Cancer, 94, 902-10. https://doi.org/10.1002/cncr.10323
- Cooperman AM (2001). Pancreatic cancer: the bigger picture. Surg Clin North Am, 81, 557-74. https://doi.org/10.1016/S0039-6109(05)70143-2
- Engelken FJ, Bettschart V, Rahman MQ, et al (2003). Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 29, 368-73. https://doi.org/10.1053/ejso.2002.1405
- Goulart BH, Clark JW, Lauwers GY, et al (2009). Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol, 16, 2-13.
- Heinemann V, Labianca R, Hinke A, et al (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol, 18, 1652-9. https://doi.org/10.1093/annonc/mdm283
- Heinemann V, Quietzsch D, Gieseler F, et al (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol, 24, 3946-52. https://doi.org/10.1200/JCO.2005.05.1490
- Ikeda M, Okada S, Tokuuye K, et al (2001). Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer, 91, 490-5. https://doi.org/10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO;2-L
- Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 59, 225-49.
- Marechal R, Demols A, Gay F, et al (2007). Prognostic factors and prognostic index for chemonaïve and gemcitabinerefractory patients with advanced pancreatic cancer. Oncology, 73, 41-51 https://doi.org/10.1159/000120627
- Nakachi K, Furuse J, Ishii H, et al (2007). Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol, 37, 114-20. https://doi.org/10.1093/jjco/hyl144
- National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma version 2.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012
- Papadoniou N, Kosmas C, Gennatas K, et al (2008). Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res, 28, 543-9.
- Royal RE, Wolff RA, Crane CH (2011). Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancerprinciples and practice of oncology. 9th ed. Philadelphia: Lippincott and Wilkins, 2011, 61-989.
- Ryan DP, Grossbard ML (1998). Pancreatic cancer:local success and distant failure. Oncologist, 3, 178-88.
- Shimoda M, Katoh M, Kita J, et al (2010). The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy, 56, 501-6. https://doi.org/10.1159/000321014
- Ueno H, Okada S, Okusaka T, et al (2000): Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology, 59, 296-301. https://doi.org/10.1159/000012186
- Viret F, Ychou M, Lepille D, et al (2004). Gemcitabine in combination with cisplatin versus gemcitabine alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol, 22, 4118. https://doi.org/10.1200/jco.2004.22.14_suppl.4118
- Yi JH, Lee J, Park SH, et al (2011). A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology, 80, 175-80. https://doi.org/10.1159/000328449
피인용 문헌
- Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7119
- Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer vol.43, pp.7, 2014, https://doi.org/10.1097/MPA.0000000000000163
- Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis vol.63, pp.8, 2014, https://doi.org/10.1007/s00262-014-1554-7
- Epidemiology of Pancreatic Cancer in Vojvodina Province in Serbia vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10779